Value in Health

Article	Citations
Author Reply	115
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations	77
Table of Contents	75
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	74
HSD101 Lack of concordance between real-world treatment patterns and clinical guideline recommendations for metastatic hormone-sensitive prostate cancer (mhspc) patients	71
RWD48 Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US	70
P32 Power Implications of Estimator Choice in Synthetic Control Arm Analyses: Results from a Simulation Comparing Average Treatment Effects on the Treated and Untreated Under Propensity Score Weightin	67
Editorial Board	67
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	66
RWD86 Healthcare Resource Utilization and Economic Burden of Patients with Gout in the United States	62
HTA35 Testing and Piloting of a Value Framework for Diagnostic Technologies in Latin America	60
EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	58
RWD116 Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions	54
EE498 Economic Burden of Interstitial Lung Disease in a Commercially Insured Population with Sjogren's Syndrome in the United States	50
RWD120 Impact of Healthcare Fragmentation on Survival of Patients with Colorectal Cancer in Colombia	50
EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database	49
HTA49 Determining Appropriate Health Economic Modeling Approaches in Fabry Disease	49
RWD118 Rapid Diversification of Immune Checkpoint Inhibitor Usage in Community Health Systems in the US Following New Drug Approvals	47
HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease	46
HTA70 Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer	45
RWD140 Using Machine Learning to Identify Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC) Patients from Electronic Health Record Data	45
RWD142 Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis	44
EPH23 Sociodemographic and Clinical Characteristics of Patients with Atopic Dermatitis in Colombia:Preliminary Results of Rendac	43
SA11 Data Visualization: A Tool to Enhance the Interpretability of Complex and Dense Data Sources	41
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib	37

PCR68 Patient-Provider Communication and Health-Related Quality of Life Among Individuals with Chronic Obstructive Pulmonary Disease in the United States	36
EPH158 Years of Life Lost Due to Diabetes Mellitus in Colombia, 1979-2017	36
SA40 Indexing Regulatory Documents and Clinical Evidence Publications for Non-Small Cell Lung Cancer (NSCLC) Therapeutics: Establishing a Dataset to Enable the Study of Endpoint Fidelity	36
EE279 A Systematic Literature Review of the Economic Burden in Patients with Myelodysplastic Syndrome	35
EPH61 Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD)	34
EPH67 Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee "Caregivers” of Patients with Breast, Skin, GI, Female, Male, and "Other” Cancers	33
EE302 Households Out-of-Pocket Healthcare Expenditures Based on Number of Chronic Conditions in Riyadh, Saudi Arabia: A Quantile Regression Approach	33
EPH69 Cancers Treatment from Their Perspective: A Qualitative Pilot Study Exploring the Knowledge Attitude and Practice of Folk Medicine Practitioners in a Low-and-Middle-Income-Country	33
EE303 Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States	33
PCR102 Leveraging Social Media for Patient Experience Insights in Rare Disease	33
PCR101 Item Response Theory Analysis of the Ilqi	33
EE139 Using a User-Friendly Modeling Tool to Inform and Guide Local Decision-Making for Lynch Syndrome Screening at Healthcare Systems	32
CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population	32
EE315 Economic Evaluation of Neutralising Monoclonal Antibodies for the Treatment of COVID-19 Positive People in the Community	31
EE154 Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US	31
HSD5 Changes in COVID-19 Treatment Patterns over the Course of 2020	30
PCR128 Rapid Review: Were There Any Clinical Trials in Non-Muscle Invasive Bladder Cancer That Naturally Adopted the Updated FDA COA Oncology Guidance?	30
HPR59 Targeted and Immunotherapies for Cancer - Reimbursement and Expenditure in a Single-Payer Healthcare System in Bulgaria	30
EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective	30
PCR153 Navigating Barriers to Patient Participation in Qualitative Interviews from International Clinical Trials in Biliary Tract Cancer (BTC)	29
PCR151 A Patient-Focused Approach to Understand Unmet Needs in Non-Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)	29
HTA72 Survival Extrapolation for Immuno-Oncology Drugs: Pessimism or Optimism? a Targeted Literature Review and a Validation-Based Case Study	28
HSD16 Trends in Rheumatology Patient Care and Practice Operations Pre- and Post-COVID-19 Pandemic	28
EE198 Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Essential Hypertension in Chinese Setting	28
EPH65 Assessment of Enzyme Preparations Consumption in Ukraine in Comparison With Other Countries of the World	27
EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada	27
EE395 Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-35 Weeks' Gestation	27
HSD79 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Tardive Dyskinesia	27
MSR30 Modelling Monthly Migraine Day Distribution: A Case Study of Fremanezumab Japanese-Korean Clinical Trials for Migraine Prevention	27
EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience	26
MSR23 A Machine Learning Approach to Score Employer Groups Based on How Well They Manage Their Specialty Drug Spend	26
MSR45 Smooth Algorithm: An Automatic Method to Estimate the Most Likely Drug Combination in Electronic Health Records. Development and Validation Study	26
EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK	26
EE406 Households Direct Economic Burden Associated with Chronic Non-Communicable Diseases in Saudi Arabia	26
HTA254 Potential Discrepancies/Misalignments in Future EU-HTA Appraisals the POLIVY and Stelara JA3 PICO Example	25
PCR16 Uncovering the Influence of Smoking on Health Care Processes for Adult Lung Cancer Patients in Chile: Insights From a Multi-Perspective Qualitative Study	25
MT36 Use of Mobile Health (MHEALTH) Applications in Cancer: A Trend Analysis	25
HTA272 EUnetHTA's HTA Core Model®: A Critical Assessment and Future Outlook	25
PCR62 Treatment Satisfaction and Health-Related Quality of Life in People Living With HIV Receiving DTG/3TC Who Are Treatment Experienced or Treatment Naive in Europe	23
HTA135 Uncertainty in AMNOG Benefit Assessments: Reflection of G-BA's Underlying Motivation to Cause AbD	23
HTA350 Fixed Effect Versus Random Effects Bayesian Network Meta-Analyses in Practice: What Is Used to Inform National Institute for Health and Care Excellence (NICE) Technology Appraisals?	23
HTA286 Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment	23
PCR49 A Preliminary Comparison between Analytical Hierarchy Process and Discrete Choice Experiment in Health State Preferences in Hong Kong SAR, China	23
EE85 Health System Costs and Resources for Stage-Specific Breast Cancer: A Population-Based Approach (Updated)	22
PCR122 Psychometric Evaluation of Multiple Sclerosis Impact Scale 29 Version 2 in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab	22
PCR117 A Qualitative Interview Study into the Experiences of Fatigue and Depression in Chronic Hepatitis B	22
HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement	22
HTA62 A Systematic Review of the New NICE Highly Specialised Technologies Criteria: How Do NICE Judge Criteria 3 and 4 to be Met?	22
PCR72 How to Achieve Comprehensive Care for Breast Cancer? Challenges in Chile from the Voice of Patients	22
RWD100 Comparison of Real-World Safety and Effectiveness of Mepolizumab and Benralizumab in the Management of Severe Asthma: A Systematic Review	22

PCR227 Do Family Spillover Effects of Illness Vary With the Age of the Ill Individual?	22
CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions	22
PCR76 Generating Health-State Utility Values in Patients Treated with Second-Line Systemic Therapy for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	22
HPR66 Assessing the Impact and Strategic Implications of the HTA Regulation 2021/20282 on National Processes: A Scoping Review and Stakeholders Perspectives Through Semi-Structured Interviews	22
EE705 The Healthcare Resource Utilisation and Associated Costs for Patients with Newly Diagnosed Fragile X Syndrome	21
RWD151 Evaluation of the Effect of Methodological Assumptions on Estimates of Adherence to Antipsychotics: A Real-World Data Study	21
HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future	21
CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)	21
EE29 Cost-Effectiveness Analysis and Budgetary Impact of Telescopic Rods for Treatment of Fractures and Correction of Bone Deformities in Children with Osteogenesis Imperfecta in the Brazilian Public	20
EE321 Cost Impact of Next Generation Sequencing Testing in NSCLC with and without RNA Sequencing	20
Copyright/Subscription	20
EE31 Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis	20
PT41 Real-World Evidence in Rare Diseases in France: Treatment Patterns, Healthcare Resource Use, and Related Costs in Von Willebrand Disease (FORvWARD Study)	20
EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia	20
EE168 Budget Impact Analysis of Adopting Lanreotide in the Treatment of Acromegaly and GEP-NET at Public Hospitals in Saudi Arabia	19
EE554 Budget Impact Analysis of Intravenous Acetaminophen in Neonates after Esophageal Atresia and Tracheoesophageal Fistula Repair	19
EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective	19
EE549 Burden of Disease of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) Using the Standard of Care in Peru	19
PCR87 Impact of Signs and Symptoms of Chronic Refractory Gout on Patient Health-Related Quality of Life	19
EE340 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation in a Developing Country	19
EE156 Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia in Colombia	19
EE372 Descriptive Analysis of Botulinum Toxin Use for Migraine and Member Costs in an Employed Population	19
EE359 Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian’s Health Syst	19
EE565 Health Economic Evaluations on Dengue Vaccine in Indonesia	18
HSD94 Assessing Payer Perspectives on Novel Therapies for the Treatment of Gorlin Syndrome	18
EPH116 Patient Pathways and Economics of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis	18
HSD113 Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis	18
EE558 Key Methodological Considerations for Developing Cost-Offset Budget Impact Models for a Range of Medical Technologies and Cost Perspectives in Ophthalmology	18
RWD4 Socioeconomic Burden of Obesity – Increased Rate and Duration of Sick Leave in Patients Living with Obesity: A Cross-Sectional Claims Data Analysis in Germany	18
MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials	18
SA56 Treatment Patterns of Advanced Egfr-Positive Non-Small Cell Lung Cancer (NSCLC) in Latin America	18
MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain	18
MSR84 Summarizing Adverse Event Data in the Absence of High-Level Evidence: The Case of Hearing Implants	18
CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea	17
EE553 An Exploratory Study Assessing the Utility Impact in Second Informal Carers of Patients With Epidermolysis Bullosa	17
EE576 Costs Saving Generated by Anti-TNF Biosimilars Market Penetration in France: An Analysis Based on French Health Insurance Open Data	17
EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial	17
HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis	17
EE573 Economic Burden of Chronic Kidney Disease with Type 2 Diabetes in Turkiye	17
EE555 Economic Burden of Cardiorespiratory Hospitalizations Associated With RSV Among US Adults, 2017-2019	17
EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer	17
EPH255 Healthcare Resource Consumption of Patients with Cardiovascular Events after Exacerbations of Chronic Obstructive Pulmonary Disease in Italy: Results from the EXACOS-CV Study	17
EE633 Analysis of Cost-Effectiveness in Switzerland for a New Implantable Device to Treat Chronic Gastroesophageal Reflux Disease	16
EE667 The Opportunity of High-Dose Vaccination Against Influenza for Adults Aged 60 and Above in the Netherlands	16
EE77 The Cost-Effectiveness of Tradition Chinese Medicine Icaritin Versus Cinobufotalin in Patients with Unresectable Advanced Hepatocellular Carcinoma in China	16
EE87 Liquid Metformin for Pediatric Patients with Metabolic Syndrome at Risk of Developing DMT2: Cost-Effectiveness Analysis in Mexican Public Health Institutions	16
EE402 Social and Economic Burden of Breast Cancer in Russia	16
EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy	16
CO56 Radiographic Progression Free Survival as a Surrogate Endpoint for Overall Survival Among Men With Metastatic Castration-Resistant Prostate Cancer	16
EPH184 The Relevance of Insomnia in Relation to Other High-Impact Pathologies. a Systematic Literature Review	16
EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population	16
HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?	16
EE458 Benefits, Costs and Cost Effectiveness of a Chronic Heart Failure Disease Management Program for Austria – a Decision-Analytic Modeling Study	16
EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece	16
HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK	16
HPR25 Patient Organisations' Submissions to the Pharmaceutical Pricing Board in Finland	15
EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada	15
HTA184 Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations	15
HTA154 Comparing Non-Oncological Rare Condition Submissions to the National Institute for Health and Care Excellence (NICE) Versus Scottish Medicines Consortium (SMC) From 2001 to 2021	15
EE476 Budget Impact Analysis of iGlarLixi for Treatment of T2DM in Algerian Setting	15
MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods	15
HTA188 Does Size Matter? Impact of Population Size on Evidence Quality and Negotiation Outcome for Orphan Drugs in Germany	15
HPR17 Changing Landscape of Orphan Drug Reimbursement - Evidence From EU-4 and England	15
RWD99 The Financial Burden of DM on the Public Health System of Greece: Using Big Data From Greece	15
EE429 Cost-Effectiveness and Budget Impact Analyses of Enzalutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer in Mexico	15
HTA196 Influence of REvalMED Pilot Program on Drug Evaluations in Spain: An Analysis of Therapeutic Positioning Reports	15
MT28 A Systematic Literature Review of the Burden Associated with Insertion of Non-Tunneled Central Venous Catheters and the Effectiveness of Ultrasound-Guided Insertion	14
HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review	14
EE172 The Wisdom Self-Management Intervention: A Cost-Effectiveness Analysis to Support the Transformation of Type 2 Diabetes Care in England	14
EPH198 Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial)	14
CO52 Impact of Digital Interventions on Maintenance Treatment Adherence in Asthma: A Systematic Literature Review (SLR) and Meta-Analysis	14
EPH168 Assessment of the Prevalence of Emotional Burnout Among Medical Workers in the Republic of Kazakhstan	14
HPR50 Challenges That EUnetHTA21 Will Have to Address to Make a Success of Joint Clinical Assessments	14
EPH142 The Burden of Metastatic or Inoperable HER2+ Breast Cancer on the Italian Health System	14
EE85 Cost-Effectiveness Analysis of GAAD Algorithm on the Detection of Early-Stage Hepatocellular Carcinoma in Patients With Chronic Liver Disease in China	14
HTA98 Distribution of the Positive Added Medical Benefit According to the Early Access Status and the Potential Public Health Interest– Analysis of the French HTA Body Opinions (HAS Transparency Commi	14
SA60 Seeking ISPOR Abstracts: Is Searching Embase Enough?	14
EPH177 Assessing Student Pharmacists’ Knowledge and Perceptions of Electronic Nicotine Delivery Systems (ENDS) – A Cross Sectional Study at One College of Pharmacy	14
CO83 Reduction of Transfusion Requirements and Length of Hospital Stay in Patients Undergoing Major Planned Surgery After the Implementation of Patient Blood Management (PBM) in Spain	14
EE506 Budget Impact Analysis of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico	14

EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan	14
PCR75 Comparing Choice Share Prediction Methods for Discrete Choice Experiments: A Case Study With Hypomethylating Agents in Myelodysplastic Syndromes	14
PCR11 Understanding the Patient Experience of Erythropoietic Protoporphyria and X-Linked Protoporphyria: A Qualitative Study	14
HSD31 Analysis of the Balanced Scorecard's Managerial Subdimensions in Health Care Organizations During the COVID-19 Pandemic	14
PCR137 A Psycho-Onco Emotional Anxiety (POEM) Framework and Application to Understanding Emotional and Psychological Burden of Living with Cancer	14
HSD53 Analysis of the Balanced Scorecard's Internal Subdimensions in Health Care Organizations During the COVID-19 Pandemic	13
EE214 Modelling Cost Determinants for Treating Metastatic Castration-Resistant Prostate Cancer: An Italian National Healthcare System's Perspective Cost Analysis	13
MSR110 A Comparison of Stan Versus WinBUGS Software for Conducting Bayesian Hazard Ratio-Based Network Meta-Analysis	13
EE375 Cost-Effectiveness Analysis of the Oncotype DX® Test to Reduce Under-Treatment in Patients With HR+/HER2- Node Negative Early-Stage Breast Cancer and Grade 2 T1C Tumours	13
PCR169 A Systematic Literature Review (SLR) of Health State Utility Values (HSUV) in Metastatic Castration-Resistant Prostate Cancer (MCRPC)	13
HSD43 COPD Patients Receiving Fixed or Open-Label Triple Therapy: Initiation and Persistence of Treatment Based on Data From a Real-World Ambulatory Medicalized Database in France	13
CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy	13
EE209 Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment in Adult Patients Following Complete Resection and Platinum-Based Chemotherapy with Non-Small Cell Lung Cancer (NSCLC) in Finlan	13
CO109 Patient-Reported Improvements in “Off”-Time Quality, Non-Motor Fluctuation Severity, and Medication Satisfaction in the Real-World Opti-on Study of Opicapone in Parkinson’s Disease	12
HPR24 Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured and after Transition to Medicare Advantage Versus Traditional Fe	12
PCR205 Assessment of Healthcare Resource Utilization in Patients with Exocrine Pancreatic Insufficiency in the Pact-CP Registry	12
HPR45 Analysis of Alternative Access Routes and Time to Access for Paediatric Indication Expansions with Consideration of Regulatory, Pricing, and Access Incentives	12
PCR195 Developing a Framework to Capture Economic Impacts on Patients and Caregivers: Recommendations to Guide Patient-Centered Outcomes Research and Value Assessment	12
Cover	12
PCR216 Insights from Social Media Posts on the Lived Experience of Alzheimer's Disease	12
EPH90 Incidence Rate of Infections and Association between Lupus Nephritis and Serious Infections in Patients with Systemic Lupus Erythematosus: Systematic Literature Review and Meta-Analyses	12
EE23 Economic Impact of Discontinuation and Relapse Rates Among Patients with Schizophrenia Newly Initiated on Lybalvi Versus Olanzapine during First Year Use	12
HPR43 The Influence and Implementation of Pathways of Care for Hematologists Compared to Oncologists in the United States	12
RWD38 Quality of Electronic Health Records: Managing Aggregated Patient Demographic Information	12
PCR222 The Value of No Cancer Signal Detected Results from Multi-Cancer Early Detection Tests–Perspectives of People in the General Population	12
HTA51 Impact of ICER Assessments on Payer Decision Making in the United States	12
EE453 Baseline Cognitive Performance Is a Determinant of Prospective Health Resource Utilization Among Adults with Chronic Stroke: A Secondary Analysis	11
RWD55 Predicting Metastatic Disease Progression in Prostate Cancer Patients Using Machine Learning of PSA Kinetics	11
RWD53 Assessing the Association of Various Characteristics with Perceived Health Status Among Adults with Skin Cancer in the United States	11
SA29 “Cash or Credit?” Feedback from Patients on the Use of Reward Programs in Digital Research	11
HPR154 Appropriate Use of Anti-PD(L)1 in Paris Public Hospitals (AP-HP): Are the Prescriptions in Compliance with Reimbursed Indications?	11
PCR238 Oral Nutritional Supplementation in Pediatric Patients Diagnosed With Leukaemia Undergoing Chemotherapy: A Review of the Literature	11
PCR150 Physicians’ Perceptions of the Impact of COVID-19 on Patient Access and Adherence	11
EPH183 Impact of a Cancer Diagnosis on Non-Cancer Chronic Disease Medication Adherence - A Systematic Literature Review	11
EE442 Direct Expenses Study of Liver Transplantation Treatment	11
HPR102 Exploring the Cost of Managing Diabetes in Nepal: A Cross-Sectional Analysis of Oral Hypoglycemic Medications	11
EE128 Facing the Challenge of Ageing: Cost-Effectiveness of the SPRINT-T Protocol	11
EE561 Estimation of the Economic Burden of Renal Complications of Diabetes in Algeria	11
Editorial Board	11
EPH244 Late-Stage Cancer Diagnosis and Systemic Therapy in England Since 2018	11
MSR15 Psychometric Validation of the Electronic Hidradenitis Suppurativa (HS) Symptom Daily Diary (eHSSDD) and Electronic HS Symptom Questionnaire (eHSSQ) Using Data from the Phase 3 BE HEARD Trials o	11
EE266 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Iron Deficiency Anemia in China	11
MSR33 Application and Feasibility of Indirect Treatment Comparison of Switch Maintenance and Non-Maintenance Oncology Regimens to Inform HTA Decision-Making	11
HPR133 Impact of International Reference Pricing (IRP) on Medicines Reimbursement Prices in Bosnia and Herzegovina	11
MSR47 Feasibility Assessment of Indirect Treatment Comparison of Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps	11
CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting	10
HSD35 If Primary Prevention Is the Solution, Why Don't We Take Advantage of All Opportunities in Brazil?	10
CO18 Reuse of Tumor Necrosis Factor Inhibitors for Treatment of Rheumatoid Arthritis Despite Discordance with Patient-Important Outcomes and Standard Disease Assessments	10
OP14 Racial and Ethnic Minority Inclusion in Clinical Outcome Assessment (COA) Research: A Reflection on Current Practices	10
HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany	10
EPH96 Risk Factors for Below-the-Knee Amputation in Japanese Patients With Critical Limb Ischemia Who Underwent Plain Old Balloon Angioplasty Therapy: A Claims Database Analysis	10
EPH118 Healthcare Systems Sustainability and Resilience: Creating an Index	10
EPH48 Evolution of Polypharmacy and Prescribed Drug Expenditure: The Case of an Insured Poor Population in the Colombian Caribbean during 2018-2021	10
EPH66 Epidemiological Population Study of Sars-Cov-2 in Lake County, Illinois: Contact: Health-Related Quality of Life Assessment	10
HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?	10
EPH82 Pharmacotherapy of Obesity in the Russian Federation: Pharmacoepidemiological Study	10
EE438 Assessing the Budget Impact of Automated Diabetic Retinopathy Screening: A Budget Impact Analysis in Germany	10
EE133 Budget Impact Related to Complications on Post-Bariatric Surgery Patients in Brazilian Public Healthcare System	10
EE220 12-Month Mortality and Healthcare Utilization in a Real-World Patient Population with Severe Tricuspid Regurgitation	10
EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France	10
HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment	10
EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study	10
HTA9 Evidence Generation Strategy and Insights for Rare Diseases: Case Studies of Mistakes Identified By NICE in Highly Specialized Technology (HST) Assessments	9
PCR243 Exploring Health Outcomes By Occupation: Using the National Health and Wellness Survey to Describe Differences in Self-Reported Occupation Profiles	9
HTA18 An Assessment of the Evolving Methods and Role of Health Equity Factors in ICER’s Final Evidence Reports	9
PCR96 Sociodemographic Variations in Perceived Social Support Among Adults with Depression in the United States: Results From the National Health and Wellness Survey	9
MSR72 An Evaluation of the Rayyan Artificial Intelligence Tool for Systematic Literature Review Screening	9
Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life	9
PCR114 Mapping Health-Related Quality of Life (HRQoL) Measures to Preference Based Measures in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A systematic literature review	9
CO139 Real-World Study of High-Risk Non-Muscle Invasive Bladder Cancer From Three Public Institutions in Mexico: Clinical Profile and Staging Patterns	9
PCR39 Preferences and Willingness to Pay of Medication for Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment	9
EE312 Multi-Comparator ICERS in Cost-Effectiveness Analysis to Account for Changes in Clinical Practice after the Introduction of a New Technology	9
HPR6 Beyond Conventional Clinical Value: Estimating the Impact of Accelerated Approvals on Therapeutic Bridging between Innovative Therapies	9
CO66 Real-World Study on Characteristics, Post-Nephrectomy Journey, and Outcomes of Patients with Early-Stage Renal Cell Carcinoma Based on Risk Groups	9
CO165 Comparison of Non-Robotic Surgery Vs. Robot-Assisted Surgery for Radical Prostatectomy	9
PCR211 Patient, Caregiver, and Physician Perspectives on the Burden of Disease Chronic Refractory Gout and Its Treatment: Concept Elicitation	9
PCR210 Association Between Caregiver Quality of Life and the Care Provided to Adults With Severe Visual Impairments: A Systematic Literature Review	9
Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data	9
Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the “Age of Cures” and Their Implications for Dynamic Efficiency	9
CO50 Analysis of Patient-Reported Outcomes of MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b Randomized, Sham-Controlled, Patient- and Assesso	9
HTA23 Broadening the Evidence Base: Incorporating Environmental Considerations Into HTAs	9
EPH54 What Do the Students Think About Food Safety Knowledge at the University of Pécs?	9
HPR146 Specialty Pharmacy Use and Adherence to Oral Anticancer Medications for Breast Cancer and Prostate Cancer: Implications for Medicare Part D Policy	9
HSD97 Treatment Utilization and Key Characteristics of COVID-19 Patients Treated with Monoclonal Antibody Therapy in the Outpatient Setting	9
EPH62 Annual Burden of Non-COVID-19 Respiratory Tract Infections in the Pre- to Post- Pandemic Eras: Analysis from the Anlitiks’ All Payor Claims Database	9
PCR127 Eliciting Patient Experience for Value Assessment in a Case Study of Spinal Muscular Atrophy	9
MSR41 The Use of Large Language Models for Systematic Literature Review Automation: An Evaluation of Quality and Time Savings	9
Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products	9
Variation in Telehealth Reimbursement After Hospital Discharge: Evidence Across Payers, Providers, and Market Characteristics	9
MSR71 Performance of AIC and BIC for the Extrapolation of Survival Data With Different Levels of Censoring	9
HTA63 Trends in Use of Cost-Minimization Analyses in CDA-AMC Reimbursement Submissions	9
MSR93 A Systematic Review of Current Evidence and Gaps on the Impact of Oral Antipsychotic Treatments in Schizophrenia	9
PCR169 Patient Involvement in Regulatory and HTA Processess: A Call for Enhanced Alignment	9
EPH52 Survey of Situation and Severity of Public Problems Affecting Health in an Industrial District in Thailand	9
PCR119 The Impacts of Age and Gender on Mapped EQ-5D-5L Utilities and Quality-Adjusted Life Years (QALYS) in Cancer Clinical Trials	9